VCYT Stock — Veracyte, Inc.

Veracyte, Inc. (VCYT)

Updated October 16, 2026.

VCYT is a Stock. Total return is 225.4% over the past 13 years, 213.2 points behind SPY at 438.6%.

Veracyte is a diagnostics company that develops and offers genomic sequencing classifiers and molecular assays to diagnose various cancers, including thyroid, prostate, bladder, breast, and lung cancer, along with nCounter analysis system services. The company does not currently pay distributions. This stock may appeal to investors seeking exposure to the molecular diagnostics and precision medicine sector rather than income-focused investors.

VCYT performance versus SPY

Price and return data through 2026-10-16.

Total return is 225.4% over the past 13 years, 213.2 points behind SPY at 438.6%. Over the past year its total return — price change plus distributions reinvested — is 20.4%. Its deepest 1-year drawdown was 39.2%.

VCYT key facts

Asset type

Stock

Asset class

Equity

Inception date

10/30/2013

Distribution frequency

None

Last close

$43.12 (as of 2026-10-16)

Market cap

$3,466,448,321

Average volume

2063233.0

Beta

1.947

Payout ratio

0.0%

P/E ratio

30.8

Forward P/E

23.5849

EPS

$1.40

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VCYT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.2%.

Who may consider VCYT — and who may not

It is a weaker fit for investors who need monthly cash flow (VCYT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VCYT

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions